Showing 6831-6840 of 7567 results for "".
- SkinCeuticals Launches Two New Cosmeceutical Cleansershttps://practicaldermatology.com/news/skinceuticals-launches-two-new-cosmeceutical-cleansers/2458048/SkinCeuticals is launching two new cleansers: Replenishing Cleanser and Smoothing Cleanser. What’s more, the original cleansers are all being repacked and reformulated. The new Replenishing Cleanser and Soothing Cleanser join SkinCeuticals&
- U.K Survey Reveals Eczema Treatment Knowledge Gaphttps://practicaldermatology.com/news/survey-reveals-eczema-treatment-knowledge-gap/2458049/Two thirds of UK eczema patients don’t understand that bacteria play a crucial role in their condition despite studies showing that Staphylococcus aureus is present on the skin in of more than 70 percent of patients, according to research from
- Happy 70th Cetaphil!https://practicaldermatology.com/news/happy-70th-cetaphil/2458051/Cetaphil is turning 70! To celebrate this milestone birthday, which takes place on Sept. 19, Cetaphil will launch a series of initiatives including: A 70-hour flash sale across retail partners nationwide running from September 17, 2017
- IPC, Others Call for Creation of Worldwide Psoriasis Databasehttps://practicaldermatology.com/news/ipc-others-call-for-creation-of-worldwide-psoriasis-database/2458055/A new report calls for the creation of a web-based Global Psoriasis Atlas (GPA) database that will document the prevalence and incidence of psoriasis worldwide. The report, entitled "Global State of Psoriasis Epidemiology: A Workshop Report,
- Five-Year Data Show Sustained Efficacy, Safety for Cosentyxhttps://practicaldermatology.com/news/five-year-data-show-sustained-efficacy-safety-for-cosentyx/2458054/Novartis’ IL-17 blocker Cosentyx® (secukinumab) maintains PASI 90 and PASI 100 response rates at five years in patients with moderate to severe plaque psoriasis, according to new Phase III data. These data were presented for
- Lilly to Present New Data for Olumiant® and Taltz® at EADVhttps://practicaldermatology.com/news/lilly-to-present-new-data-for-olumiant-and-taltz-eadv/2458060/Eli Lilly and Company will present Phase 2 safety and efficacy data evaluating Olumiant® (baricitinib) for the treatment of moderate-to-severe atopic dermatitis (Lilly and Incyte Corporation are partners on the develo
- Two Galderma Rosacea Therapies Work Well Togetherhttps://practicaldermatology.com/news/two-galderma-rosacea-therapies-work-well-together/2458061/Combined use of Galderma’s SOOLANTRA (ivermectin1% Cream) and Mirvaso (Brimonidine 0.33% Gel) pack a one-two punch against the erythema and inflammatory lesions of rosacea, the MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCe
- Dermira Presents New Data on Late-Stage Programs at European Dermatology Congresshttps://practicaldermatology.com/news/dermira-presents-new-data-on-late-stage-programs-at-european-dermatology-congress/2458066/Dermira, Inc. will present data from its glycopyrronium tosylate (formerly DRM04) and Cimzia (certolizumab pegol) Phase 3 clinical programs in poster sessions at the 26th European Academy of Dermatology and Venereology (EADV) Congress, taking place in Geneva, Switzerland, September 13&
- GBI Research: Global Dermatology Pipeline Will See Shift Toward Increased Use of Biologicshttps://practicaldermatology.com/news/gbi-research-global-dermatology-pipeline-to-see-shift-toward-increased-use-of-biologics/2458071/The global dermatology pipeline, which currently comprises 850 products with a disclosed stage of development, is primarily made up of drugs at an early stage of development, with the late stages of the pipeline dominated by generics and biosimilars, according to GBI Research. The company
- FDA Greenlights Humira Biosim Cyltezo for Multiple Inflammatory Diseaseshttps://practicaldermatology.com/news/fda-greenlights-humira-biosim-cyltezo-for-multiple-inflammatory-diseases/2458073/The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim Pharmaceuticals, Inc.’s Cyltezo™, a biosimilar to Humira®, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including: